MENU
+Compare
ALLK
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$0.29
Change
-$0.00 (-0.00%)
Capitalization
25.53M

ALLK Allakos Forecast, Technical & Fundamental Analysis

a provider of antibody therapeutics for allergic and inflammatory diseases

Industry Biotechnology
ALLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALLK with price predictions
Feb 21, 2025

ALLK saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for ALLK moved out of overbought territory on February 20, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In of the 62 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

ALLK moved below its 50-day moving average on January 27, 2025 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for ALLK moved below the 200-day moving average on February 05, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALLK broke above its upper Bollinger Band on February 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALLK entered a downward trend on February 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALLK's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 10, 2025. You may want to consider a long position or call options on ALLK as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALLK just turned positive on February 13, 2025. Looking at past instances where ALLK's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLK advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.351) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). ALLK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (251.221).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ALLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLK is expected to report earnings to fall 10.33% to -18 cents per share on March 04

Allakos ALLK Stock Earnings Reports
Q4'24
Est.
$-0.19
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.03
Q1'24
Missed
by $0.37
Q4'23
Missed
by $0.24
The last earnings report on November 07 showed earnings per share of -20 cents, beating the estimate of -25 cents. With 617.22K shares outstanding, the current market capitalization sits at 25.53M.
A.I. Advisor
published General Information

General Information

a provider of antibody therapeutics for allergic and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
825 Industrial Road
Phone
+1 650 597-5002
Employees
131
Web
https://www.allakos.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELVN21.800.33
+1.54%
Enliven Therapeutics
MOVE5.00-0.01
-0.20%
Movano Inc
AVB218.92-0.46
-0.21%
AvalonBay Communities
JMSB17.70-0.63
-3.44%
John Marshall Bancorp
RARE42.59-1.89
-4.25%
Ultragenyx Pharmaceutical

ALLK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLK has been loosely correlated with VERU. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLK jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLK
1D Price
Change %
ALLK100%
-1.72%
VERU - ALLK
48%
Loosely correlated
-2.88%
AXON - ALLK
38%
Loosely correlated
-5.28%
IMCR - ALLK
33%
Loosely correlated
+0.17%
AMRN - ALLK
32%
Poorly correlated
-0.82%
GANX - ALLK
31%
Poorly correlated
-2.99%
More